Development of allogeneic iPS cell‐based therapy: from bench to bedside
This commentary provides a brief overview of the steps necessary for the generation of an induced pluripotent stem (iPS) cell‐derived clinical grade product. This process requires extensive, proper documentation as well as a thoughtful and systematic optimization of the manufacturing methods to ensu...
Main Authors: | David H McKenna, Rita C R Perlingeiro |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2023-02-01
|
Series: | EMBO Molecular Medicine |
Online Access: | https://doi.org/10.15252/emmm.202115315 |
Similar Items
-
The Hantaviruses of Europe: from the Bedside to the Bench
by: Jan Clement, et al.
Published: (1997-06-01) -
CAR-T Cell Therapy: From the Bench to the Bedside
by: Vita Golubovskaya
Published: (2017-10-01) -
Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
by: Francesco Pelliccia, et al.
Published: (2022-08-01) -
HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration
by: Sunao Sugita, et al.
Published: (2020-07-01) -
Bench and Bedside
by: Schmidt Christian
Published: (2002-07-01)